Hence, there is a connection between the CYP2D6 polymorphisms and the plasma levels of antidepressants; and MDD patients need a dose of antidepressant appropriate to their genetic characteristics to achieve better efficacy and fewer side effects. Here, CYP2D6 is linked to major depressive disorder.